newsfilter
← Latest News
GlobeNewswire·

Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

– Company actively monitoring delays to mitigate potential impact of COVID-19 and conflict in Ukraine following Russian invasion on the estimated completion dates for the trial – Patient enrollment expected to continue into 2023 TOR